<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In several large phase II trials, low-dose treatment with the azanucleoside <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi> (<z:chebi fb="0" ids="50131">decitabine</z:chebi>, DAC) resulted in complete hematologic and cytogenetic responses in 23 and 31% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, respectively </plain></SENT>
<SENT sid="1" pm="."><plain>The question of induction of <z:mp ids='MP_0008866'>chromosomal instability</z:mp> by this demethylating agent was addressed by serial karyotypic analyses </plain></SENT>
<SENT sid="2" pm="."><plain>53/122 DAC-treated patients had <z:hpo ids='HP_0000001'>all</z:hpo> <z:mpath ids='MPATH_458'>normal</z:mpath> metaphases at time of treatment start </plain></SENT>
<SENT sid="3" pm="."><plain>In 46/53 patients, sequential cytogenetic analyses were performed </plain></SENT>
<SENT sid="4" pm="."><plain>9/46 patients (20%) acquired clonal chromosomal abnormalities during follow-up (4/9 transient) </plain></SENT>
<SENT sid="5" pm="."><plain>8/9 abnormalities were gains or losses of entire chromosomes </plain></SENT>
<SENT sid="6" pm="."><plain>The rate and pattern of cytogenetic evolution are thus not higher than in historical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cohorts not receiving specific treatment </plain></SENT>
</text></document>